The antibody cocktail reduces the risk of hospitalization by 70 percent.

The Phase 3 trials have shown that REGEN-COV antibody reduced hospitalization and death by 70 percent in COVID-19 patients.

The Phase 3 trials have shown that REGEN-COV antibody reduced hospitalization and death by 70 percent in COVID-19 patients. A monoclonal antibody cocktail was authorized for emergency use by the FDA in November 2020. Regeneron had collaborated with Roche to develop, manufacture and distribute REGN-COV2, an anti-viral antibody cocktail.

The clinical trials showed that the therapy reduces the 70 percent risk of hospitalization and death in patients at high risk of developing severe illness due to COVID-19 infection. It also significantly decreased the disease progression within 28 days after treatment when compared to placebo. The therapy was carried out in mild and moderate patients suffering from COVID-19. However, we don't have actual efficacy data yet.

The treatment involves administering a mixture of casirivimab and imdevimab, which blocks the virus's attachment and entry into cells. The Monoclonal antibodies are artificially created in the lab, and the cocktail was used to treat former United States President Donald Trump.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.